Core Insights - Coeptis Therapeutics Holdings, Inc. has rebranded to COEPTIS, indicating a strategic shift to expand beyond biopharmaceuticals into technology-driven sectors [1][3] - The establishment of a new Technology Division aims to enhance operational capabilities and maximize shareholder value, highlighted by the acquisition of the NexGenAI Affiliates Network platform [1][6] - The integration of NexGenAI's tools will empower COEPTIS to address marketing challenges with AI-driven precision and efficiency, focusing on automation and workflow optimization [2][6] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company dedicated to developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [5] - COEPTIS is committed to advancing treatment paradigms and improving patient outcomes through cutting-edge research and development efforts [4][5] Technology Division - The newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation [6] - This division aims to optimize business processes and improve overall efficiency, positioning COEPTIS as a self-sustaining entity for long-term growth and profitability [3][6]
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation